Business
BioRestorative Therapies Announces Notice of Allowance for New Patent Application in Japan and Expansion of ThermoStem® IP Portfolio
Notice of Allowance Grants Protection for Generating Implantable Three-Dimensional Scaffolds MELVILLE, N.Y., Feb. 02, 2022 (GLOBE NEWSWIRE) -- BioRestorative
About this update from Biorestorative Therapies, Inc.
[{"type":"text","content":"Notice of Allowance Grants Protection for Generating Implantable Three-Dimensional Scaffolds MELVILLE, N.Y., Feb. 02, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a life sciences company focused on stem cell-based therapies, today announced that the Japanese Patent Office has issued a notice of allowance for a patent application related to the Company’s metabolic ThermoStem® Program. The notice of allowance was issued on January 26, 2022 and is related to a new patent application not previously announced. Claims granted under the new patent cover implantable three-dimensional scaffolds and brown adipocytes from human brown adipose-derived stem cells. The combination of scaffolds as a delivery system and brown adipose derived stem cells provides the ability to deliver metabolically active cells. Therapeutic benefits of using brown adipose have been demonstrated in various models and may provide a valuable therapeutic tool for treating a range of metabolic disorders. “We continue to see success developing a comprehensive global patent portfolio for ThermoStem® and this latest notice of allowance further strengthens our overall IP position in using scaffolds as a delivery system.\" said Lance Alstodt, the Company’s CEO \"The claims of this application are the result of BioRestorative’s expertise in applying cell therapy to treat metabolic disorders. They underscore the potential value of ThermoStem® as a novel treatment for diseases such as diabetes and obesity, which represent major unmet needs.\" About BioRestorative Therapies, Inc. BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders: • Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient’s...